A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
A phase 1/2 trial of Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Kahr Medical, active and no longer recruiting.
Overview
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04440735 by Kahr Medical, with 125 participants planned, started 2020-10-07 and due to reach its primary completion in 2025-09. Interventions recorded: DSP107, Atezolizumab. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Shares Atezolizumab, Colorectal cancer.
- TrialBlood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
Shares Atezolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialQuaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Shares Atezolizumab, Small-cell lung cancer.
- TrialTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shares Atezolizumab, Small-cell lung cancer.
- TrialA Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Shares Atezolizumab, Small-cell lung cancer.